EP Lab Digest

CardioFocus, Inc. today announced that the first U.S. patients have been treated commercially with the recently-approved HeartLight® X3 Endoscopic Ablation System.

In 2018, health spending in the U.S. was $3.6 trillion (17.7% of gross domestic product [GDP]) with a projection to reach nearly $6.0 trillion by year 2027 (one-fifth of GDP).

Catheter ablation for ventricular arrhythmias (VA) has become increasingly common with the advent of more sophisticated three-dimensional mapping systems and irrigated-tip radiofrequency (RF) catheters with contact force sensing ability.

Since the outbreak of COVID-19, we’ve seen an increase in mainstream telehealth, FaceTime for visits, waiving out-of-pocket expenses, working from home, and reporting office visit codes for telehealth services.

The world is facing an unprecedented modern pandemic that has posed many new challenges to healthcare providers.

Percutaneous catheter ablation with a strategy of scar modification is a validated technique for management of ventricular tachycardia (VT) and is particularly advantageous in the setting of multiple hemodynamically unstable circuits.

The cardiac electrophysiology (EP) program at The University of Kansas Health System (KU) in Kansas City is one of the largest electrophysiology programs in the Midwest offering comprehensive services in all domains in electrophysiology.

Percutaneous catheter ablation with a strategy of scar modification is a validated technique for management of ventricular tachycardia (VT) and is particularly advantageous in the setting of multiple hemodynamically unstable circuits.

In this interview, we speak with Rajesh Venkataraman, MD, FHRS from Houston Methodist the Woodlands Hospital in The Woodlands, Texas.

Chris* knew something was not working right with his heart, but this felt different from his previous heart attack five years ago.